Drug intelligence / Profile preview

SteadyTeq

Development stage
Unknown
Lead developer
Teva Pharmaceutical Industries
Modality
Small Molecules, Hydrogel Systems → Drug Delivery Systems
Administration
Subcutaneous
01

Overview

SteadyTeq is a proprietary copolymer-based drug delivery technology developed by MedinCell and licensed to Teva Pharmaceuticals. It serves as the delivery platform for UZEDY (risperidone), an FDA-approved extended-release injectable suspension for the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in adults. The technology, internally referred to by MedinCell as BEPO, creates a subcutaneous biodegradable depot that slowly releases risperidone—an atypical antipsychotic—over a period of one or two months. This formulation allows for rapid therapeutic onset (within 6–24 hours) and eliminates the requirement for oral supplementation or loading doses typically associated with long-acting injectables.

Brand names
UZEDY
Other names
BEPO
02

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on SteadyTeq.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SteadyTeq.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call